Inhye Ahn, MD (@inhyeahn) header
Inhye Ahn, MD (@inhyeahn) profile picture

Inhye Ahn, MD

@inhyeahn

Hematologist-oncologist | CLL Researcher | Faculty @DanaFarber | Graduate of @NIH Fellowship

 Boston, MA
Danafarber.org
Joined August 2015
  • Tweets14
  • Following174
  • Followers287
5Media
Photo by Inhye Ahn, MD (@inhyeahn)Photo by Inhye Ahn, MD (@inhyeahn)Photo by Inhye Ahn, MD (@inhyeahn)Photo by Inhye Ahn, MD (@inhyeahn)Photo by Inhye Ahn, MD (@inhyeahn)
What did we learn from the past decade with ibrutinib in #CLL? #NIH phase 2 study data presented by Dr. Adrian Wiestner showed: - Median PFS of 81 months for TN-CLL with TP53 alterations - Median PFS was even longer for TN-CLL without TP53 alterations - IGHV status matters.
Image from Inhye Ahn, MD (@inhyeahn)
1
15
817
Excellent session at #iwCLL2023 on prevention of infection by @carsten_niemann, Clare Sun, Yair @herishanu, Carolyn Owen, and Chris Pleyer. Going home with new and practical ideas on vaccination in #CLL.
Image from Inhye Ahn, MD (@inhyeahn)
10
741
Thanks #DAVABermudaHeme for the chance to be part of this amazing meeting.
Kathryn Gallaway, MD (@KE_Gallaway) profile pictureKathryn Gallaway, MD@KE_Gallaway27 Jul 2023
Replying to @inhyeahn
@inhyeahn kicks off our BTKi session with an excellent overview of resistance mechanisms in CLL. As BTKi options continue to expand, deep understanding of the development of these mutations will help guide sequencing strategies and novel MOAs for future agents. #DAVABermudaHeme
Image from Kathryn Gallaway, MD (@KE_Gallaway)
9
1,017
A reunion with @DrSwami_Iyer in @icmlugano who was my attending during residency training—it was just a few years back :D
Image from Inhye Ahn, MD (@inhyeahn)
1
13
1,030
B and NK cell docs on a lunch date! Had a wonderful time with @romeerizwan and Ji Eun Jang, our visiting professor from @yonseiunivon, at a Korean restaurant.
Image from Inhye Ahn, MD (@inhyeahn)
2
1
1
18
1,656
Welcoming @JiEunJang120 to Twitter!
177
Big change to NCCN guidelines which now include pirtobrutinib for double exposed CLL pts - hopefully this helps with insurance coverage for pts who aren’t able to do clinical trials #cllsm
Image from calliecoombs (@calliecoombsmd)
1
14
63
6,349
Check out our latest work on transcriptomic profiles of #CLL, drivers of MRD response and 5-year results from CLL14 – all out today in one paper @NatureComms : nature.com/articles/s41467-0… Key results in a brief 🧵
4
25
3
77
15,645
Great end to an exciting #ASH21 conference with an amazing talk by @DrMDavids on therapies for p53 mutant hematologic malignancies - making inroads in an important area of unmet clinical need!
Image from Christine Ryan, MD (@ChristineRyanMD)
2
14
Delighted to share our latest paper in #JCO, in which we suggest an MRD growth model of CLL, including new data from the CLL14 study (Ven-Obi vs Clb-Obi). #leusm #GCLLSG @ASCO_pubs bit.ly/2ZyAVEZ Some results in a quick 🧵 1/n
1
11
62
Start of a new era here in the @DanaFarber CLL Center. First official clinic day for our newest CLL expert @inhyeahn. Welcome Dr. Ahn!
Image from Matthew Davids, MD, MMSc (@DrMDavids)
8
6
151
Dr. Gulley @gulleyj1 talks about #Immunotherapy combination strategy at #AACR17. @NCICCR_MOS
Image from Inhye Ahn, MD (@inhyeahn)
1
1
1
1
Load more